Spero Therapeutics, Inc.
SPRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,048 | $11,802 | $5,874 | $15,044 |
| % Growth | -74.2% | 100.9% | -61% | – |
| Cost of Goods Sold | $0 | $0 | $13,606 | $94,634 |
| Gross Profit | $3,048 | $11,802 | -$7,732 | -$79,590 |
| % Margin | 100% | 100% | -131.6% | -529% |
| R&D Expenses | $8,597 | $10,672 | $13,606 | $28,836 |
| G&A Expenses | $4,174 | $5,878 | $6,824 | $6,264 |
| SG&A Expenses | $4,174 | $5,878 | $6,824 | $7,056 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $792 |
| Other Operating Expenses | -$1,807 | -$2,304 | -$13,431 | -$93,757 |
| Operating Expenses | $10,964 | $14,246 | $6,999 | -$57,865 |
| Operating Income | -$7,916 | -$2,444 | -$14,731 | -$21,725 |
| % Margin | -259.7% | -20.7% | -250.8% | -144.4% |
| Other Income/Exp. Net | $534 | $744 | $865 | $1,127 |
| Pre-Tax Income | -$7,382 | -$1,700 | -$13,866 | -$20,598 |
| Tax Expense | $0 | $0 | $0 | $290 |
| Net Income | -$7,382 | -$1,700 | -$13,866 | -$20,888 |
| % Margin | -242.2% | -14.4% | -236.1% | -138.8% |
| EPS | -0.13 | -0.03 | -0.25 | -0.39 |
| % Growth | -329% | 87.9% | 35.9% | – |
| EPS Diluted | -0.13 | -0.03 | -0.25 | -0.39 |
| Weighted Avg Shares Out | 56,281 | 56,027 | 55,376 | 54,038 |
| Weighted Avg Shares Out Dil | 56,281 | 56,027 | 55,376 | 54,038 |
| Supplemental Information | – | – | – | – |
| Interest Income | $532 | $740 | $864 | $1,028 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$7,382 | -$2,361 | -$14,556 | -$20,848 |
| % Margin | -242.2% | -20% | -247.8% | -138.6% |